Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit (Haplo/Cord)

This study has been terminated.
(Only one patient was enrolled. Due to low accrual study was terminated)
Sponsor:
Information provided by (Responsible Party):
Parameswaran Hari, Medical College of Wisconsin
ClinicalTrials.gov Identifier:
NCT01050946
First received: January 14, 2010
Last updated: October 21, 2015
Last verified: October 2015
  Purpose

This study is a means of providing transplantation to those patients who would be a stem cell transplant candidate who do not have an appropriate donor.

The use of CD34 selected haploidentical donor with an umbilical cord unit may help provide earlier engraftment without the need for long term immunosuppression.

This study tests a new method of bone marrow transplantation called combined haploidentical-cord blood transplantation. In this procedure, some of the blood forming cells (the stem cells) from a partially human leukocyte antigen (HLA) matched (haploidentical) related donor are collected from the blood, as well as cells from an umbilical cord are transplanted into the patient (the recipient) after administration of a "conditioning regimen". A conditioning regimen consists of chemotherapy and sometimes radiation to the entire body (total body irradiation, or TBI), which is meant to destroy the cancer cells and suppress the recipient's immune system to allow the transplanted cells to take (grow).


Condition Intervention Phase
Leukemia, Lymphocytic, Acute
Leukemia, Lymphocytic, Chronic
Leukemia, Myelocytic, Acute
Leukemia, Myeloid, Chronic
Lymphoma, Non-Hodgkin
Lymphoma, Hodgkins
Biological: Haploidentical/cord transplant
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study: HSCT Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit

Resource links provided by NLM:


Further study details as provided by Medical College of Wisconsin:

Primary Outcome Measures:
  • The Primary Objective is to Estimate the Overall Survival, Separately in the Two Risk Strata. [ Time Frame: 3 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Time to Relapse: To Assess the Incidence of Acute Leukemia or Lymphoma Relapse From Day of Transplant [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    NOT analyzed since there was only patient and no relapse was observed till patient passed away

  • Time to Neutrophil Engraftment: To Assess the Incidence of Neutrophil Engraftment From Day of Transplant [ Time Frame: 100 days ] [ Designated as safety issue: No ]
    time to neutrophil recovery after transplant

  • Time to Platelet Engraftment: To Assess the Incidence of Platelet Engraftment From Day of Transplant, [ Time Frame: 100 days ] [ Designated as safety issue: No ]
  • Time to Acute GVHD: We Will Assess the Incidence and Severity of Grades II-IV and Grades III-IV Acute GVHD From Day of Transplant. [ Time Frame: 100 days ] [ Designated as safety issue: No ]
  • Transplant Related Mortality (TRM): TRM is Death Occurring in Patients in Continuous Complete Remission. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
  • Disease-free Survival:Death or Relapse Will be Considered Events for This Endpoint. [ Time Frame: 3 years ] [ Designated as safety issue: No ]

Enrollment: 1
Study Start Date: July 2009
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Haploidentical/cord transplant
Haploidentical/cord transplant with the precondition regimen at discretion of treating physician.
Biological: Haploidentical/cord transplant

Myeloablative preparative regimen of chemotherapy and radiation followed by mismatch related(haploidentical)donor and one unit umbilical cord blood transplantation.

Conditioning Regimens Choice of regimen at the discretion of the treating physician

  1. Fludarabine 30mg/m2(Days-7,-6,-5,-4,-3)-,Melphalan 70mg/m2(Day -3,-2), ATG 1.5mg/m2(Day-7,-5,-3,-1)
  2. Fludarabine 50mg/m2(Day -6,-5,-4,-3,-2),Busulfan 3.2mg/kg(Day -5,-4,-3,-2),400cGY Total Body Irradiation(TBI)Day-1,ATG 1.5mg/kg(Day-7,-5,-3,-1)

Day 0 -Haploidentical donor and one umbilical cord blood unit infusion

Other Name: Cord Blood Transplant

Detailed Description:

This method of stem cell transplantation is designed to overcome some of the limitations of other alternative donor transplant options. Use of unrelated umbilical cord unit (UCB) donors appears to allow a greater degree of HLA mismatch with acceptable rates of GVHD. However, when UCB transplant was studied in the adult population, investigators discovered several limitations. One major limitation with UCB was delayed engraftment, resulting in higher risk of infection in the early post transplant period. The limitations to cord blood transplant involve delayed engraftment resulting in early complications such as infections. The main limitation associated with haploidentical donors is the significant immunosuppression required to prevent/treat aGVHD. Use of this combined modality of transplantation appears to allow for rapid neutrophil engraftment from the haploidentical donor and coupled with long term hematopoiesis from the UCB donor, thus requiring less long term immunosuppression.

This study tests a new method of bone marrow transplantation called combined haploidentical-cord blood transplantation. In this procedure, some of the blood forming cells (the stem cells) from a partially HLA matched (haploidentical) related donor are collected from the blood, as well as cells from an umbilical cord are transplanted into the patient (the recipient) after administration of a "conditioning regimen". A conditioning regimen consists of chemotherapy and sometimes radiation to the entire body (total body irradiation, or TBI),

One of two 'conditioning regimens' which will be determined by the physician.

  1. FLUDARABINE, MELPHALAN, ATG

    Fludarabine 30mg/m2(Days-7,-6,-5,-4,-3)-,Melphalan 70mg/m2(Day -3,-2), ATG 1.5mg/m2(Day-7,-5,-3,-1)

  2. FLUDARABINE, BUSULFAN, 400 CGY TBI, ATG Fludarabine 50mg/m2(Day -6,-5,-4,-3,-2),Busulfan 3.2mg/kg(Day -5,-4,-3,-2) 400cGY Total Body Irradiation(TBI)Day-1,ATG 1.5mg/kg(Day-7,-5,-3,-1)

Day 0 -Haploidentical donor and one umbilical cord blood unit infusion

Filgrastim will be administered daily from day +1 until blood counts have completely recovered. Tacrolimus and another immunosuppressant, Cellcept, starting before transplant also to reduce the risks of graft versus host disease and to promote the growth of the graft. Tacrolimus will be given daily from two days before the transplant until at least three months after transplantation. Cellcept, will be tapered after the cells engraft.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients between 18 and 65 years old
  • Patient has a related family member(haploidentical) or unrelated which is 5 of 10 HLA identical match.

Standard Risk

  • Acute myelogenous leukemia: CR1 with high risk cytogenetics or molecular abnormalities such as FLT-3 ITD, or CR2 with a first remission that must have lasted > 1 year.
  • Acute Lymphocytic Leukemia: CR1, in order to be standard risk must NOT have Philadelphia Chromosome.
  • Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Must be refractory to fludarabine or fail to have a complete or partial response after therapy with a regimen containing fludarabine (or another nucleoside analog, e.g. 2-CDA, pentostatin) or experience disease relapse within 12 months after completing therapy with a regimen containing fludarabine (or another nucleoside analog).
  • Chronic myelogenous leukemia: resistant to or intolerant of TKI, in CP1 or CP2, or with a mutation that suggests resistance to TKI.
  • Myelodysplastic Syndrome: RA, RARS, must be IPSS ≥ INT-2, Blasts <5%.

High Risk Patients:

  • Acute myelogenous leukemia: Patients with CR2 are considered high risk if they have high risk cytogenetics, or molecular abnormalities or CR1 lasted for less than 1 year. Any evidence of active disease or no blasts in an acellular marrow.
  • Acute Lymphocytic Leukemia: CR1- with Ph+ disease, CR2/+ with any cytogenetics. Any evidence of active disease.
  • Chronic myelogenous leukemia- CP2/+, AP1/+, resistant or intolerant to TKI.
  • Hodgkin's or Non Hodgkin's lymphoma- Disease recurrence following an autologous transplant, or high risk disease not thought to benefit from autologous transplant.
  • Chronic lymphocytic leukemia- that is resistant to fludarabine, and never has been in remission or with stable disease/progressive disease
  • Multiple myeloma: Must have had prior treatment. Patients in CR2 or greater can be considered, must have already failed autologous transplant Previous autologous transplant,must have been greater than 6 months prior to undergoing this transplant.
  • Myelodysplastic syndrome: RAEB
  • Other Myeloproliferative disorders including myelofibrosis, spent phase p Vera,Essential thrombocytosis,CMML.

Exclusion Criteria:

  • Patients <18 years old Disease related criteria
  • APML, presence of t(15,17) in first CR
  • Patients with good risk AML, for example t(8;21), or inv 16, or normal cytogenetics with FLT-3-ITD negative, NPM-1 positive disease in 1st CR
  • MDS IPSS < INT-2 Miscellaneous Criteria
  • Recipients who have a matched related sibling or unrelated donor
  • If recipient has evidence of anti-HLA antibodies directed against cord or haplo-donor as determined byflowPRA.

Underlying health criteria:

  • Zubrod performance status > 2 (see Appendix E)
  • Life expectancy is limited to less than 8 weeks by concomitant illness
  • Patients with severely decreased LVEF (EF < 40%)
  • Impaired pulmonary function tests (PFT's) (FVC, FEV1, DLCO < 45% predicted)
  • Estimated Creatinine Clearance <50 ml/min
  • Serum bilirubin> 2.0 mg/dl or SGPT >3 x upper limit of normal
  • Evidence of chronic active hepatitis or cirrhosis
  • HIV-positive
  • Patient is pregnant
  • Patient or guardian not able to provide informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01050946

Sponsors and Collaborators
Medical College of Wisconsin
Investigators
Principal Investigator: Jeanne Palmer, M.D. Medical College of Wisconsin
  More Information

Responsible Party: Parameswaran Hari, Professor of Medicine, Medical College of Wisconsin
ClinicalTrials.gov Identifier: NCT01050946     History of Changes
Other Study ID Numbers: MCW 11491 
Study First Received: January 14, 2010
Results First Received: August 26, 2015
Last Updated: October 21, 2015
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Keywords provided by Medical College of Wisconsin:
Unrelated Umbilical Cord Blood Transplant(UCB)
CD34+ Selected mismatched related donor
Haploidentical donor
hematopoietic stem cell transplantation(HSCT)
ALL
Leukemia, Lymphocytic, Acute
AML
Leukemia, Myelocytic, Acute
CML
Leukemia, Myeloid, Chronic
NHL
Lymphoma, Non-Hodgkin
HL
Lymphoma, Hodgkins

Additional relevant MeSH terms:
Lymphoma
Leukemia
Lymphoma, Non-Hodgkin
Leukemia, Myeloid
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Acute
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Hodgkin Disease
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases

ClinicalTrials.gov processed this record on September 30, 2016